1-5 of 5
Sharmila Das
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Fabian Mueller, Krish Patel, Ran Reshef, Mohamad Cherry, Richard Nash, Ernesto Ayala, Jingmei Hsu, Jacques Azzi, Peter Vandenberghe, Roch Houot, Bastian von Tresckow, Giuseppina Stifano, Ashley Koegel, Susana Falcon, Burhan Chaudhry, Lisa Kelly, Jerill Thorpe, Alyse Frisbee, Sam Charab, Sharmila Das, Thomas Ly, Ken Ogasawara, Paolo Caimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2088.
https://doi.org/10.1182/blood-2024-194525
Published: 2024
Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

David Lavie, Vincent Ribrag, Michael Loschi, Costas K. Yannakou, Maan Alwan, Adi Schacham Abulafia, Jesús María Hernández-Rivas, Yulia Volchek, Chun Yew Fong, Massimiliano Bonifacio, Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Valentín García Gutiérrez, Alessandra Tucci, Blanca Xicoy, Haifa Kathrin Al-Ali, Moshe Talpaz, Jonathan M. Gerber, Indu Raman, Ciprian Tomuleasa, Si Tuen Lee-Hoeflich, Sharmila Das, Bin Wu, Qian Zhao, Eunhee Kim, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Rosa Ayala
Journal: Blood
Blood (2023) 142 (Supplement 1): 623.
https://doi.org/10.1182/blood-2023-179160
Published: 2023
Journal Articles

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

Si Tuen Lee-Hoeflich, Christopher Brueckner, Lawrence Litalien, Ke Xu, Sharmila Das, Laura Corella, Sherif Daouti, Oriana Esposito, Emma Lees, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Bin Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3158.
https://doi.org/10.1182/blood-2023-181620
Published: 2023
Journal Articles

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Henry Chang, Sharmila Das, Bin Wu, Palanikumar Ravindran, Vivian Shan, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie
Journal: Blood
Blood (2022) 140 (Supplement 1): 9665–9667.
https://doi.org/10.1182/blood-2022-159476
Published: 2022
Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard
Journal: Blood
Blood (2022) 140 (Supplement 1): 1360–1362.
https://doi.org/10.1182/blood-2022-160038
Published: 2022